Skip to main content

Search Videos and More

Showing 1 - 10 of 10 results

Antibody-Drug Conjugates: A Cancer Therapy Revolution

Antibody-Drug Conjugates: A Cancer Therapy Revolution

Dana-Farber researchers explore how a novel therapy may benefit patients

Dana-Farber Study Finds Up-front Chemotherapy Boost Could Benefit Patients with Non-Small Cell Lung Cancer

Dana-Farber Study Finds Up-front Chemotherapy Boost Could Benefit Patients with Non-Small Cell Lung Cancer

In a phase 3 global clinical trial called FLAURA2 led by researchers from Dana-Farber Cancer Institute and Institut Gustav Roussy in France, patients with non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation taking standard therapy plus chemotherapy had a median of nearly 9 months increase in progression free survival compared with patients taking standard therapy alone.

Study Uncovers Epigenetic Source of Resistance to Targeted Therapy in EGFR-mutant Lung Cancer

Study Uncovers Epigenetic Source of Resistance to Targeted Therapy in EGFR-mutant Lung Cancer

When lung cancers driven by mutations in the EGFR gene become resistant to osimertinib or other targeted therapies, epigenetic changes, rather than genetic changes, are often to blame.

In Memoriam: Arthur T. Skarin, MD, Physician-Scientist Instrumental in Building Dana-Farber’s Adult Oncology Program

In Memoriam: Arthur T. Skarin, MD, Physician-Scientist Instrumental in Building Dana-Farber’s Adult Oncology Program

The Dana-Farber community mourns the passing of Arthur T. Skarin, MD, of Needham, Massachusetts.

Immunotherapy Combination Shown to Benefit Some Patients with Non-Small Cell Lung Cancer Resistant to Single Immunotherapy

Immunotherapy Combination Shown to Benefit Some Patients with Non-Small Cell Lung Cancer Resistant to Single Immunotherapy

A combination of two drugs that open the floodgates to an immune system attack on cancer curtailed tumor growth in some patients with non-small cell lung cancer (NSCLC) that was resistant to a single immunotherapy agent, results from a recent clinical trial show.

Highlights in Lung Cancer From ESMO 2021 - Pasi Jänne, MD, PhD, Discusses Promising Studies from the Meeting

Highlights in Lung Cancer From ESMO 2021 - Pasi Jänne, MD, PhD, Discusses Promising Studies from the Meeting

In this exclusive MedPage Today video, ESMO Scientific Co-Chair Pasi A. Jänne, MD, PhD, director of the Chen-Huang Center for EGFR-Mutant Lung Cancer at Dana-Farber Cancer Institute in Boston, highlights some of the important lung cancer abstracts from the conference.

Lung Cancer Research at ESMO

Lung Cancer Research at ESMO

Dana-Farber's Pasi A. Jänne, MD, PhD, provides insight on DESTINY-Lung01 trial in lung cancer highlighted at ESMO 2021.

Antibody-Drug Conjugate Shows Impressive Activity in Patients with Non-Small Cell Lung Cancer with Mutation in HER2 Gene

Antibody-Drug Conjugate Shows Impressive Activity in Patients with Non-Small Cell Lung Cancer with Mutation in HER2 Gene

More than half of patients with non-small cell lung cancer (NSCLC) bearing a mutation in the HER2 gene had their tumors stop growing or shrink for an extended time after treatment with a drug that hitches a chemotherapy agent to a highly targeted antibody, an international clinical trial led by investigators at Dana-Farber Cancer Institute has found.

New Research Uncovers How Cancers with Common Gene Mutation Develop Resistance to Targeted Drugs

New Research Uncovers How Cancers with Common Gene Mutation Develop Resistance to Targeted Drugs

Multiple acquired resistance mechanisms discovered for cancers with KRASG12C mutation after treatment with KRASG12C inhibitors.

Level of Chromosomal Abnormality in Non-small Cell Lung Cancer May Predict Response to Immunotherapy

Level of Chromosomal Abnormality in Non-small Cell Lung Cancer May Predict Response to Immunotherapy

Dana-Farber researchers find patients whose tumors have low aneuploidy levels often have better outcomes following treatment with immune checkpoint inhibitors.